News, whether actionable or not and share pricing are the starting points where an investment decision for action begins.

RMi evaluates collected "intelligence" and historical "patterns", then rationalizes a "seasoned" interpretation to develop a pricing probability and a “tight” thesis that identifies with sector comparables in the RegMed, stem, cell and gene therapy sector separating fact from science fiction . 

What RMI understands is the short -pre-open and aftermarket, near-term investment opportunity. 

Timeliness of an investment is critical - sifting through analyst reports and newsletters printed days, weeks or even months in advance doesn't realize price appreciation or a decline.

So pardon the pun – “where’s the meat and what is the price - now”?  RMi provides … facts - first,  fast and based on vetted information.